| Q51391212 | A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. |
| Q38739234 | A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. |
| Q37399469 | Assessment of fibrosis in chronic liver diseases |
| Q39130543 | Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease |
| Q30451362 | Can NASH be diagnosed, graded, and staged noninvasively? |
| Q58622671 | Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? |
| Q35768951 | Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease |
| Q34812618 | Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease |
| Q26828855 | Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries |
| Q35946481 | Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. |
| Q35495753 | Diagnosis and evaluation of nonalcoholic fatty liver disease |
| Q33491250 | Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis |
| Q27496667 | Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease |
| Q33263279 | Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease |
| Q30467234 | Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography |
| Q36958949 | Effects of one-time and two-time intra-articular injection of hyaluronic acid sodium salt after joint surgery in dogs |
| Q58478066 | Esteatosis hepática no alcohólica. Puesta al día |
| Q33612450 | Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia |
| Q24644869 | Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers |
| Q27021754 | Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis |
| Q26752723 | Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies |
| Q37572860 | Implication of normal liver enzymes in liver disease |
| Q37205152 | Is there a place for serum laminin determination in patients with liver disease and cancer? |
| Q30407625 | Liver fibrosis markers of nonalcoholic steatohepatitis |
| Q37222778 | Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection |
| Q30403258 | MR Elastography of Liver Disease: State of the Art. |
| Q34662500 | New clinical score to diagnose nonalcoholic steatohepatitis in obese patients |
| Q33866383 | Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy |
| Q26800894 | Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway |
| Q37613375 | Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease |
| Q37192623 | Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. |
| Q37801658 | Non-invasive assessment of liver fibrosis: it is time for laboratory medicine |
| Q37386095 | Non-invasive diagnosis of steatosis and fibrosis. |
| Q35769146 | Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. |
| Q53605149 | Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. |
| Q58816508 | Nonalcoholic Fatty Liver Disease in Severely Obese Subjects |
| Q37699734 | Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment |
| Q37632281 | Nonalcoholic fatty liver disease in children living in the obeseogenic society |
| Q33706254 | Nonalcoholic fatty liver disease: Diagnostic biomarkers. |
| Q36382279 | Nonalcoholic fatty liver disease: from steatosis to cirrhosis |
| Q30435948 | Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease |
| Q59050387 | Noninvasive Biomarkers of Liver Fibrosis: An Overview |
| Q36744614 | Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). |
| Q34256132 | Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. |
| Q38141711 | Noninvasive evaluation of NAFLD. |
| Q35233535 | Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis |
| Q30464608 | Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. |
| Q36656294 | Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease |
| Q33384921 | Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). |
| Q84587493 | Prolidase and oxidative stress in chronic hepatitis C |
| Q33886918 | Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis |
| Q52699058 | Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. |
| Q39215323 | Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil. |
| Q34207845 | Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease |
| Q51372036 | Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. |
| Q51791871 | Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. |
| Q34830398 | Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| Q37078109 | Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. |
| Q61989968 | The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD |
| Q101038911 | The impact of endotrophin on the progression of chronic liver disease |
| Q80387912 | Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage |
| Q46345522 | Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis |
| Q45127401 | Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease |
| Q36280695 | ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population |